EP4608396A1 — Treatment of iga nephropathy using an endothelin receptor antagonist and an april binding antibody
Assigned to Aduro Biotech Holdings Europe BV · Expires 2025-09-03 · 1y expired
What this patent protects
The present disclosure relates to the use of an endothelin receptor antagonist, or a pharmaceutically acceptable salt thereof, and isolated antibodies, including antigen-binding fragments thereof, which bind human APRIL for the treatment of IgA nephropathy.
USPTO Abstract
The present disclosure relates to the use of an endothelin receptor antagonist, or a pharmaceutically acceptable salt thereof, and isolated antibodies, including antigen-binding fragments thereof, which bind human APRIL for the treatment of IgA nephropathy.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.